VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors
July 07 2021 - 8:30AM
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical
company committed to developing a new generation of medicines with
the potential to go beyond the current standard of care for
anxiety, depression and other central nervous system (“CNS”)
disorders, today announced the appointment of Mary L. Rotunno, J.D.
to its Board of Directors (“Board”).
“Mary brings to our team more than 30 years of
leadership experience, which began with serving patients as a
registered nurse and transitioned to serving clients in health care
law, both allowing her to pursue her steadfast commitment to
helping others and advancing the future of mental health and
wellness,” said Shawn Singh, Chief Executive Officer of VistaGen.
“Her extensive track record as an advocate for both patients and
health care providers is unique and will provide deep and valuable
insights into strategies for value-based care and an understanding
of the entire life cycle of the mental healthcare experience. Mary
has also served as a trusted advisor on complex governance,
regulatory and compliance requirements for several companies. Her
strategic vision, skill for scenario planning, and enterprise risk
management expertise will be key in the next phases of our
corporate development as we continue to pursue our core mission -
to improve mental health and well-being for individuals in the U.S.
and abroad.”
Ms. Rotunno is currently General Counsel and
Member of the Executive Leadership Team at El Camino Health, a $1
billion revenue health care system. She is also Board Chair and a
member of Audit, Executive/Governance and Nominations Committees
for health care provider, Momentum for Health, in Silicon Valley.
Before joining El Camino Health in early 2014, Ms. Rotunno spent
over 11 years as Senior Counsel and Client Service Leader for
Common Spirit Health, formerly Dignity Health, in San Francisco Bay
Area. Prior to Dignity Health, she held various legal roles at
Varian Medical Systems, Manatt, Phelps & Phillips, Golden
Living, and Pillsbury Winthrop Shaw Pitman. She graduated with
honors from the University of Illinois with a Bachelor of Science
in Nursing. She worked as a registered nurse before earning her
Juris Doctor degree, cum laude, from the University of California,
Hastings College of Law, San Francisco. She obtained certification
by the Women’s Corporate Board Readiness Program at Santa Clara
University and completed the Hastings Leadership Academy for Women
and Dignity Health Ministry Leadership Program.
About VistaGenVistaGen
Therapeutics is a biopharmaceutical company committed to developing
and commercializing innovative medicines with the potential to go
beyond the current standard of care for anxiety, depression, and
other CNS disorders. Each of VistaGen's three drug candidates has a
differentiated potential mechanism of action, has been
well-tolerated in all clinical studies to date, and has therapeutic
potential in multiple CNS markets. For more information, please
visit www.VistaGen.com and connect with VistaGen on
Twitter, LinkedIn, and Facebook.
Forward Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the federal securities laws. These forward-looking
statements involve known and unknown risks that are difficult to
predict and include all matters that are not historical facts. In
some cases, you can identify forward-looking statements by the use
of words such as “may,” “could,” “expect,” “project,” “outlook,”
“strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “strive,” “goal,” “continue,”
“likely,” “will,” “would” and variations of these terms and similar
expressions, or the negative of these terms or similar expressions.
Such forward-looking statements are necessarily based upon
estimates and assumptions that, while considered reasonable by us
and our management, are inherently uncertain. Our actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference are fully discussed in the section entitled "Risk
Factors" in our most recent Annual Report on Form 10-K for the
fiscal year ended March 31, 2021, as well as discussions of
potential risks, uncertainties, and other important factors in our
other filings with the U.S. Securities and Exchange Commission
(SEC). Our SEC filings are available on the SEC’s website at
www.sec.gov. You should not place undue reliance on these
forward-looking statements, which apply only as of the date of this
press release and should not be relied upon as representing our
views as of any subsequent date. We explicitly disclaim any
obligation to update any forward-looking statements, other than as
may be required by law. If we do update one or more forward-looking
statements, no inference should be made that we will make
additional updates with respect to those or other forward-looking
statements.
VistaGen Company ContactsMark McPartland / Mark
FlatherVistaGen Therapeutics Phone: (650) 577-3606Email:
IR@vistagen.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024